Mechanisms of resistance to immune checkpoint inhibitors

Immune checkpoint inhibitors (ICI) targeting CTLA-4 and the PD-1/PD-L1 axis have shown unprecedented clinical activity in several types of cancer and are rapidly transforming the practice of medical oncology. Whereas cytotoxic chemotherapy and small molecule inhibitors ('targeted therapies'...

Full description

Saved in:

Bibliographic Details
Published in:	British journal of cancer Vol. 118; no. 1; p. 9
Main Authors:	Jenkins, Russell W, Barbie, David A, Flaherty, Keith T
Format:	Journal Article
Language:	English
Published:	England Nature Publishing Group 01.01.2018
Subjects:	Animals Biomarkers Cancer Chemotherapy CTLA-4 protein Cytotoxicity Drug Resistance, Neoplasm Humans Immune checkpoint inhibitors Immune response Immunologic Factors - pharmacology Immunologic Factors - therapeutic use Immunotherapy Lymphocytes T Molecular Targeted Therapy Neoplasms - drug therapy Neoplasms - immunology PD-1 protein PD-L1 protein Signal Transduction - drug effects T-Lymphocytes - drug effects Tumors
ISSN:	0007-0920, 1532-1827, 1532-1827
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!